Search clinical trials for: OX40L/TNF bispecific antibody

Total 5308 results

IMBiologics Corp.

Not yet recruiting

A Study of IMB-101 in Healthy Volunteers and Participants With Rheumatoid Arthritis

Rheumatoid Arthritis
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular Lymphoma | Refractory Grade 2 Follicular Lymphoma | Refractory Grade 3a Follicular Lymphoma

United States
University of Washington

Not yet recruiting

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal Zone Lymphoma and other conditions

United States
Wuhan YZY Biopharma Co., Ltd.

Recruiting

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Malignant Ascites

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC (LungCadX)

NSCLC

China
Hansoh BioMedical R&D Company

Not yet recruiting

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy...
Akesobio

Not yet recruiting

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Pleural Mesothelioma
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)

Neoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast Cancer

China
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer (QUEEN-Neo)

Neoadjuvant Therapy | Early Breast Cancer | HR+HER2- Breast Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectable

China
Wuhan Union Hospital, China
Xiangya Hospital of Central South University; Sun Yat-sen University; The Affiliated... and other collaborators

Not yet recruiting

A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Advanced Soft-tissue Sarcoma
Shanghai Zhongshan Hospital
Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Hepatocellular Carcinoma

China
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Thomas Martin, MD
Bristol-Myers Squibb; Janssen Research & Development, LLC

Not yet recruiting

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
National Cancer Institute (NCI)

Not yet recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma | Follicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Gastric Cancer | Esophagogastric Junction Cancer

China
Meng Chao Hepatobiliary Hospital of Fujian Medical...

Not yet recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

China
SparX Biotech(Jiangsu) Co., Ltd.

Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303)

Solid Tumor | CRC | HNSCC | RCC

United States
C. Babis Andreadis
Eli Lilly and Company; Genentech, Inc.; Adaptive Biotechnologies

Not yet recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma

United States
Academic and Community Cancer Research United

Not yet recruiting

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Primary Mediastinal Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Taiwan, Spain, Korea, Republic of, Thailand, Italy, Malaysia, Turkey, Australia
Pfizer
Bristol-Myers Squibb

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

United States, Canada
Harbin Medical University

Not yet recruiting

A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Pfizer

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

United States, Japan, Spain, Canada, Finland, Argentina, Norway
Fusion Pharmaceuticals Inc.
AstraZeneca

Not yet recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma

United States, Canada
Nanfang Hospital, Southern Medical University

Not yet recruiting

First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lung Non-Small Cell Carcinoma
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Follicular Lymphoma

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Spain, Korea, Republic of, Belgium, Austria, Thailand, Singapore, Italy, Turkey, France, Australia, Czechia, Poland, Chile, United Kingdom, Germany
Fujian Cancer Hospital
The First Affiliated Hospital of Nanchang University; Fujian Provincial Hospital and other collaborators

Not yet recruiting

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Endometrial Cancer | Endometrial Adenocarcinoma
Pfizer

Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (MagnetisMM15)

Multiple Myeloma

Canada, France, Japan, Australia, United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
RenJi Hospital
Shanghai Zhongshan Hospital; Ruijin Hospital

Recruiting

A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy

China
Guangzhou Excelmab Inc.

Recruiting

Safety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

CD20-positive Non-Hodgkin Lymphoma

China
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

United States
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
German Cancer Research Center

Recruiting

FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer (CoRe_CC-3)

Colorectal Cancer

Germany
Shanghai Zhongshan Hospital

Recruiting

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Biliary Tract Cancer | Candonilimab | Claudin 18.2

China
SCRI Development Innovations, LLC
Janssen Research & Development, LLC

Recruiting

Outpatient Administration of Teclistamab for Multiple Myeloma

Multiple Myeloma

United States
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Smoldering Multiple Myeloma (SMM)

Spain
Hansoh BioMedical R&D Company

Not yet recruiting

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Non-Small Cell Lung Cancer | Solid Tumor

China
Sun Yat-sen University

Recruiting

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Pleural Mesothelioma

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
David Ho
US Military HIV Research Program; Henry M. Jackson Foundation for the Advancement... and other collaborators

Recruiting

10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults

HIV-1-infection

Tanzania
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell Lymphoma

United States

Search clinical trials for: OX40L/TNF bispecific antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations